Viking registers Phase 3 oral VK2735 trial in type 2 diabetes obesity
SUNRISE 2 is the second of two Phase 3 studies supporting an oral weight-management indication, with dosing set to begin October 16, 2026.
PR
By Priya Raman · Science Reporter
Oct 9 08:00 ETSource: ClinicalTrials.gov
The wire
- 01ClinicalTrials.gov lists NCT07868939, a 68-week randomized, double-blind, placebo-controlled study of oral VK2735 in adults with type 2 diabetes and BMI at or above 27 kg/m2.
- 02An oral incretin from Viking would compete directly with orforglipron and oral semaglutide, and a diabetes-population trial broadens the potential label beyond obesity alone.
- 03The registration is not yet recruiting and no efficacy data are reported; the record states only design, duration and start date.
From the source
Read at clinicaltrials.govOral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
NCT07868939 · PHASE3 · NOT YET RECRUITING · Sponsor: Viking Therapeutics, Inc. · Conditions: Weight Loss.
Source URL https://clinicaltrials.gov/study/NCT07868939
